NAME: Guo, Charles Chuanhai

eRA COMMONS USER NAME (credential, e.g., agency login): guocc

POSITION TITLE:  Associate Professor of Pathology

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION DEGREE(if applicable) Completion Date FIELD OF STUDY

Qingdao University Medical College, China                   MD                         7/1990              Medicine

Chinese Academy of Medical Sciences, Beijing             M.Sc                       6/1993              Molecular Biology

University of Iowa College of Medicine                       Postdoctoral             1/1995              Pharmacology

Oregon National Primate Research Center                  Postdoctoral             10/1995            Neuroscience

New York University Medical Center                          Residency                7/2005              Pathology

Johns Hopkins University School of Medicine               Fellowship                 7/2006             Genitourinary Pathology

A.  Personal Statement

I am an academic pathologist with a strong interest in translational cancer research. I received extensive training in both clinical pathology and laboratory research with additional subspecialty training in genitourinary pathology. As a surgical pathologist, I analyze a variety of biopsy and surgical specimens from genitourinary cancers, including prostate, urinary bladder, kidney, and testicular cancers and provide valuable pathologic information, which helps to establish a specific diagnosis, optimize a treatment plan and predict a clinical course for the patient. My laboratory research is focused on comparing the gene expression profiles of conventional and variant urothelial carcinoma. I also study the genetic alteration, particularly the TMPRSS2-ERG gene fusion, in prostate cancer.

B.  Positions and Honors

Positions and Employment

1993-1994   Research Fellow, Department of Physiology, Chinese Academy of Medical Sciences, Beijing, China

1995-1998   Research Associate, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN

1998-2001  Research Associate, Departments of Surgery and Cancer Biology, Duke University Medical Center, Durham, NC

2006-2012  Assistant Professor, Department of Pathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

2012-present   Associate Professor, Department of Pathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

Other Experience and Professional Memberships

1997- Associate Member and Member, American Association for Cancer Research

2001- Member, United States and Canadian Academy of Pathology

2005- Member, International Society of Urologic Pathology

2005- American Board of Pathology Certification in Anatomic and Clinical Pathology

2006- Fellow, College of American Pathologists

2009- MD Anderson Intuitional Research Grants Program, Study section committee for clinical, translational and population-based projects

Honors

1990 Academic Excellence Scholarships, Qingdao University Medical School, Shandong, China

2004 Academic Excellence Scholarships, Chinese Academy of Medical Sciences, Beijing, China

2009 Armstrong Cancer Biology Award, Duke comprehensive Cancer Center, Durham, NC

C. Contribution to Science

1. Prostate cancer is a complex disease characterized by multiple molecular alterations. My early research was focused on elucidating the role of protein kinases, CK2 and MAP, in prostate cancer. Using both in vivo and in vitro approaches, I demonstrated that the function of CK2 and MAP was regulated by androgen in prostate cancer. In addition, I found another key enzyme, telomerase, was essential to cancer development and progression and was also under the control of androgen in prostate cancer.

a. Guo C, Davis AT, Yu S, Tawfic S, Ahmed K. Role of protein kinase CK2 in phosphorylation nucleosomal proteins in relation to transcriptional activity. Mol Cell Biochem 191:135-42, 1/1999.

b. Guo C, Yu S, Davis AT, Ahmed K. Nuclear matrix targeting of the protein kinase CK2 signal as a common downstream response to androgen or growth factor stimulation of prostate cancer cells. Cancer Res 59:1146-51, 3/1999.

c. Guo C, Luttrell LM, Price DT. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 163:1027-1032, 3/2000.

d. Guo C, Yu S, Davis AT, Wang H, Green JE, Ahmed K. A potential role of nuclear matrix associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J Biol Chem 276:5992-5999, 2/2001.

e. Guo C, Geverd D, Liao R,Hamad N, Counter CM, Price DT. Inhibition of telomerase is related to the lifespan and tumorigenicity of human prostate cancer cells. J Urol 166:694-698, 8/2001.

f. Guo C, Armbruster BN, Price DT, Counter CM. In vivo regulation of hTERT expression and telomerase activity by androgen. J Urol 170:615-618, 8/2003

2. Prostate cancer frequently exhibits recurrent gene fusions, most commonly the TMPRSS2-ERG gene fusion.  My recent research evaluated the TMPRSS2-ERG gene fusion in prostate cancer of different zonal origins. I found that the TMPRSS2-ERG gene fusion was less common in prostate cancers arising from the transition zone than those of the peripheral zone. I also demonstrated the TMPRSS2-ERG gene fusion was also present in small cell carcinoma of the prostate and it encoded two different transcripts. Additionally, my research showed that there was a high consistency of the TMPRSS2-ERG gene fusion in matched primary and metastatic prostate cancer specimens.

a. Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol 22:866-71, 7/2009

b. Guo CC, Troncoso P, Wang Y, Xiao L and Czerniak B. TMPRSS2-ERG gene fusion in transition zone prostate cancer. Mod Pathol 23:1041-1042, 7/2010

c. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG Gene Fusion in Small Cell Carcinoma of the Prostate. Hum Pathol 42:11-17, 1/2011

d. Guo CC, Wang Y, Xiao L, Troncoso P, Czerniak BA. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Hum Pathol 43:644-9, 05/2012

e. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol 19:1528-35, 12/2006.

f. Guo CC, Pisters LL, Troncoso P. Prostate cancer invading the rectum: a clinicopathological study of 18 cases. Pathology 41:539-43, 6/2009.

3. Although most bladder cancers are composed of conventional urothelial carcinoma, some exhibit histologic variants that are characterized by distinct clinical and pathologic features.  I evaluated clinicopathologic features of several aggressive UC variants, including micropapillary, plasmacytoid, sarcomatoid and small cell carcinoma. I demonstrated that GATA-3, uroplakin II and III were differentially expressed in UC variants. I also analyzed the pathology and tissue quality of MDACC bladder cancer specimens that were used in the bladder cancer genome atlas project.

a. Guo CC, Fine SW, Epstein JI. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases. Am J Surg Pathol 30(7):883-91, 7/2006.

b. Guo CC, Gomez E, Tamboli P, Bondaruk JE, Kamat A, Bassett R, Dinney CP, Czerniak BA. Squamous Cell Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Study of 16 Cases. Hum Pathol 40(10):1448-52, 10/2009.

c. Guo CC, Tamboli P, Czerniak B. Micropapillary variant of urothelial carcinoma in the upper urinary tract: a clinicopathologic study of 11 cases. Arch Pathol Lab Med 133(1):62-6, 1/2009.

d. Stanton ML, Xiao L, Czerniak B, Guo CC. Urothelial Tumors of the Urinary Bladder in Young Patients: A Clinicopathologic Study of 59 Cases. Archives of Pathology & Laboratory Medicine 137(10):1337-1344, 10/2013.

e. The Cancer Genome Atlas Research Network (including Guo CC). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315-22, 03/2014

f. Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Human Pathology. 45(7):1466-72, 07/2014

g. Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, Czerniak B, Guo CC. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. American Journal of Clinical Pathology. 142(6):864-71, 12/2014

4. In addition, I conducted several clinical and pathologic studies of testicular germ cell tumors, particularly in the area of somatic transformation.

a. Guo CC, Punar M, Contreras AL, Tu SM, Pisters L, Tamboli P, Czerniak B. Testicular Germ Cell Tumors with Sarcomatous Components: An Analysis of 33 cases. Am J Surg Pathol 33(8):1173-8, 8/2009

b. Contreras AL, Punar M, Tamboli P, Tu SM, Pisters L, Moran C, Czerniak BA, Guo CC. Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases. Hum Pathol 41:832-7, 6/2010.

c. Tarrant WP, Czerniak BA, Guo CC. Relationship between Primary and Metastatic Testicular Germ Cell Tumors: A Clinicopathologic Analysis of 100 Cases. Human Pathol 44:2220-2226, 10/2013.

Complete List of Published Work:

http://www.ncbi.nlm.gov/pubmed/?term=Guo+CC